Unknown

Dataset Information

0

Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study.


ABSTRACT: Tenofovir disoproxil fumarate is associated with renal and bone toxicity. In a single-arm, open-label study of 242 virologically suppressed, HIV-infected participants with creatinine clearance 30-69 mL/min who switched to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide, participants had stable creatinine clearance, significant and durable improvements in proteinuria, albuminuria, and tubular proteinuria (P < 0.001), and significant increases in hip and spine bone mineral density through 96 weeks (P < 0.001). Eighty-eight percent maintained HIV-1 RNA <50 c/mL at week 96. These longer-term results support the use of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-infected individuals with mild-moderately impaired renal function.

SUBMITTER: Post FA 

PROVIDER: S-EPMC5228610 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study.

Post Frank A FA   Tebas Pablo P   Clarke Amanda A   Cotte Laurent L   Short William R WR   Abram Michael E ME   Jiang Shuping S   Cheng Andrew A   Das Moupali M   Fordyce Marshall W MW  

Journal of acquired immune deficiency syndromes (1999) 20170201 2


Tenofovir disoproxil fumarate is associated with renal and bone toxicity. In a single-arm, open-label study of 242 virologically suppressed, HIV-infected participants with creatinine clearance 30-69 mL/min who switched to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide, participants had stable creatinine clearance, significant and durable improvements in proteinuria, albuminuria, and tubular proteinuria (P < 0.001), and significant increases in hip and spine bone mineral density thro  ...[more]

Similar Datasets

| S-EPMC6425939 | biostudies-literature
| S-EPMC4804743 | biostudies-literature
| S-EPMC7899215 | biostudies-literature
| S-EPMC7776806 | biostudies-literature
| S-EPMC5172523 | biostudies-literature
| S-EPMC5942200 | biostudies-literature
| S-EPMC6667714 | biostudies-literature
| S-EPMC7727346 | biostudies-literature
| S-EPMC6221083 | biostudies-literature
| S-EPMC6039393 | biostudies-literature